These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10445371)

  • 21. Effects of zaleplon or triazolam with or without ethanol on human performance.
    Roehrs T; Rosenthal L; Koshorek G; Mangano RM; Roth T
    Sleep Med; 2001 Jul; 2(4):323-332. PubMed ID: 11438249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of zaleplon, a non-benzodiazepine hypnotic, on melatonin secretion in rabbits.
    Noguchi H; Kitazumi K; Mori M; Shiobara Y; Shiba T
    J Pharmacol Sci; 2003 Oct; 93(2):204-9. PubMed ID: 14578589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers.
    Mintzer MZ; Frey JM; Yingling JE; Griffiths RR
    Behav Pharmacol; 1997 Nov; 8(6-7):561-74. PubMed ID: 9832970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic profile of SKP-1041, a modified release formulation of zaleplon.
    Greenblatt DJ; Harmatz JS; Walsh JK; Luthringer R; Staner L; Otmani S; Nedelec JF; Francart C; Parent SJ; Staner C
    Biopharm Drug Dispos; 2011 Dec; 32(9):489-97. PubMed ID: 21935965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefit-risk assessment of zaleplon in the treatment of insomnia.
    Barbera J; Shapiro C
    Drug Saf; 2005; 28(4):301-18. PubMed ID: 15783240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trazodone and triazolam: acute subject-rated and performance-impairing effects in healthy volunteers.
    Rush CR; Madakasira S; Hayes CA; Johnson CA; Goldman NH; Pazzaglia PJ
    Psychopharmacology (Berl); 1997 May; 131(1):9-18. PubMed ID: 9181630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers.
    Mintzer MZ; Griffiths RR
    Behav Pharmacol; 2005 Nov; 16(7):579-84. PubMed ID: 16170235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.
    Drover DR
    Clin Pharmacokinet; 2004; 43(4):227-38. PubMed ID: 15005637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharma-clinics. Drug of the month. Zaleplon (Sonata)].
    Ansseau M
    Rev Med Liege; 1999 Aug; 54(8):705-6. PubMed ID: 10548901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent.
    Patat A; Paty I; Hindmarch I
    Hum Psychopharmacol; 2001 Jul; 16(5):369-392. PubMed ID: 12404558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of zaleplon on learning and memory in rats.
    Noguchi H; Kitazumi K; Mori M; Shiba T
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):183-8. PubMed ID: 12122506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers.
    Farré M; Terán MT; Camí J
    Psychopharmacology (Berl); 1996 May; 125(1):1-12. PubMed ID: 8724443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.
    Zawertailo LA; Busto UE; Kaplan HL; Greenblatt DJ; Sellers EM
    J Clin Psychopharmacol; 2003 Jun; 23(3):269-80. PubMed ID: 12826989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects in humans after repeated administrations of zolpidem and triazolam.
    Stoops WW; Rush CR
    Am J Drug Alcohol Abuse; 2003 May; 29(2):281-99. PubMed ID: 12765207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB.
    Carter LP; Richards BD; Mintzer MZ; Griffiths RR
    Neuropsychopharmacology; 2006 Nov; 31(11):2537-51. PubMed ID: 16880774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triazolam-amphetamine interaction: dissociation of effects on memory versus arousal.
    Mintzer MZ; Griffiths RR
    J Psychopharmacol; 2003 Mar; 17(1):17-29. PubMed ID: 12680736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychomotor effects of zaleplon and thioridazine coadministration.
    Hetta J; Broman JE; Darwish M; Troy SM
    Eur J Clin Pharmacol; 2000 Jun; 56(3):211-7. PubMed ID: 10952475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zaleplon: a review of its use in the treatment of insomnia.
    Dooley M; Plosker GL
    Drugs; 2000 Aug; 60(2):413-45. PubMed ID: 10983740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia.
    Weitzel KW; Wickman JM; Augustin SG; Strom JG
    Clin Ther; 2000 Nov; 22(11):1254-67. PubMed ID: 11117652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia.
    Drake CL; Roehrs TA; Mangano RM; Roth T
    Hum Psychopharmacol; 2000 Dec; 15(8):595-604. PubMed ID: 12404612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.